Acute Respiratory Distress Syndrome (ARDS) Treatment Market to Reach USD 3.66 Billion by 2035, Driven by Rising ICU Admissions and Key Players AbbVie, Pfizer, Medtronic & Dräger

The global Acute Respiratory Distress Syndrome (ARDS) Treatment Market was valued at USD 2.16 billion in 2025 and is projected to reach USD 3.66 billion by 2035, expanding at a CAGR of 5.8% during the forecast period from 2026 to 2035. The market is gaining importance as severe respiratory complications associated with pneumonia, sepsis, trauma, and other critical illnesses continue to drive demand for intensive-care interventions. Growing adoption of lung-protective ventilation, extracorporeal membrane oxygenation (ECMO), oxygen therapies, and advanced critical-care monitoring is creating opportunities for pharmaceutical and medical-device companies. Rising ICU capacity, improved diagnosis of severe respiratory failure, and increasing focus on reducing mortality and ventilator-related complications are further supporting demand for advanced ARDS management solutions.

A major opportunity is emerging around next-generation ARDS treatment and precision critical care, with companies and research organizations focusing on improved respiratory-support technologies, targeted therapies, and data-driven patient management. Advances in AI-assisted respiratory monitoring, smart ventilators, ECMO systems, novel anti-inflammatory therapies, and personalized treatment protocols are opening new avenues for innovation. The growing need to improve outcomes in critically ill patients is also encouraging investment in technologies that can optimize oxygenation while minimizing ventilator-induced lung injury. As healthcare systems continue strengthening critical-care infrastructure and pharmaceutical and medical-device companies pursue more effective ARDS interventions, the market is positioned for steady long-term expansion.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID): https://www.datamintelligence.com/download-sample/acute-respiratory-distress-syndrome-treatment-market?sai-v

Recent Developments
July 2026: Breathe Biologics advanced development of JadiCellTM, an investigational umbilical cord-derived mesenchymal stem cell therapy for ARDS, with a Phase III study scheduled to begin in July 2026. The 128-patient study is evaluating intravenous JadiCell in patients with ARDS, reflecting growing interest in regenerative approaches for severe lung injury.

June 2026: BioAegis Therapeutics continued the Phase II development of BTI-203 (rhu-pGSN) for moderate-to-severe ARDS associated with pneumonia and other infections. The multicenter study is evaluating rhu-pGSN alongside standard care, with recruitment planned across multiple international clinical sites, supporting the development of host-directed therapies for ARDS.

May 2026: MiNK Therapeutics dosed the first patient in its randomized Phase II trial of agenT-797, an off-the-shelf allogeneic invariant natural killer T (iNKT) cell therapy, in patients with severe acute lung injury meeting ARDS criteria. The trial is evaluating agenT-797 with standard care and represents an emerging cell-therapy approach for acute respiratory injury.

April 2026: Southeast University, China initiated preparations for the Phase III DEFEND trial evaluating dexamethasone plus usual care in patients with sepsis-associated ARDS. The multicenter, randomized, double-blind study is designed to assess whether dexamethasone can reduce 90-day mortality, reflecting continued investigation of pharmacological approaches targeting inflammation in ARDS.

March 2026: Southeast University and the Chinese ARDS Research Network advanced the EITVent2 clinical program evaluating electrical impedance tomography (EIT)-guided PEEP selection in ARDS. The multicenter randomized trial, which began in March 2026, is designed to assess individualized ventilatory strategies and their impact on clinical outcomes, strengthening the role of precision ventilation in ARDS management.

Key Players
AbbVie Inc. | Pfizer Inc. | Medtronic Plc | Drägerwerk AG & Co. KGaA | Shenzhen Mindray Bio-Medical Electronics Co., Ltd. | Beijing Aeonmed Co., Ltd. | ONY Biotech Inc. | Par Pharmaceutical Inc. | Merit Pharmaceutical | Narang Medical Limited | Others

Key Highlights
AbbVie Inc. - Holds a 18.6% share, driven by its respiratory and critical care pharmaceutical portfolio, innovative therapies, and strong global healthcare presence.

Pfizer Inc. - Holds a 16.2% share, supported by its broad pharmaceutical portfolio, respiratory disease therapies, clinical development capabilities, and extensive global distribution network.

Medtronic Plc - Holds a 14.8% share, strengthened by its respiratory care technologies, critical care devices, ventilation solutions, and advanced patient monitoring systems.

Drägerwerk AG & Co. KGaA - Holds a 12.7% share, fueled by its ventilators, anesthesia workstations, respiratory monitoring systems, and intensive care technologies.

Shenzhen Mindray Bio-Medical Electronics Co., Ltd. - Holds a 10.9% share, driven by its respiratory care equipment, patient monitoring systems, ventilators, and cost-effective critical care technologies.

Beijing Aeonmed Co., Ltd. - Holds a 8.4% share, supported by its mechanical ventilators, anesthesia machines, respiratory care systems, and critical care equipment portfolio.

ONY Biotech Inc. - Holds a 6.3% share, strengthened by its neonatal respiratory care technologies, surfactant therapies, and treatments supporting premature infants with respiratory complications.

Par Pharmaceutical Inc. - Holds a 4.5% share, driven by its pharmaceutical products, specialty therapies, and focus on respiratory and critical care treatment areas.

Merit Pharmaceutical - Holds a 3.2% share, supported by its pharmaceutical manufacturing capabilities, specialty drug portfolio, and healthcare product development activities.

Narang Medical Limited - Holds a 2.1% share, fueled by its respiratory care equipment, CPAP systems, ICU equipment, medical devices, and broad healthcare equipment distribution network.

Others - Hold a combined 2.3% share, comprising regional pharmaceutical companies, respiratory device manufacturers, specialty drug developers, and critical care technology providers focused on advanced respiratory treatment and intensive-care solutions.

Buy Now - Instant Access to the Full Report: https://www.datamintelligence.com/buy-now-page?report=acute-respiratory-distress-syndrome-treatment-market?sai-v

Market Drivers
Rising ICU admissions from pneumonia, sepsis, and other severe respiratory conditions are driving demand for ARDS treatment.

Growing use of mechanical ventilation, corticosteroids, ECMO, and advanced supportive care is supporting market growth.

Increasing focus on lung-protective ventilation and evidence-based ARDS management is accelerating adoption of advanced critical-care therapies.

The global ARDS Treatment Market was valued at USD 2.14 billion in 2025 and is projected to reach USD 3.76 billion by 2035, growing at a 5.8% CAGR.

Market Opportunities
Growing demand for regenerative therapies and disease-modifying ARDS treatments is creating significant opportunities.

Advancements in stem-cell therapies, targeted anti-inflammatory treatments, and personalized critical care are expanding the development pipeline.

Increasing clinical research into ECMO, corticosteroids, neuromuscular blockers, and advanced ventilation strategies is supporting innovation.

March 2026: Breathe Biologics submitted an FDA request for RMAT designation for JadiCell, an umbilical-cord-derived mesenchymal stem-cell therapy for ARDS.

Industry Developments
Advanced mechanical ventilation, ECMO, digital respiratory monitoring, and regenerative therapies are transforming ARDS management.

May 2026: Breathe Biologics submitted additional clinical information to the FDA supporting its RMAT review for JadiCell in ARDS.

July 2026: Breathe Biologics began its Phase III JadiCell clinical study for ARDS, registered as NCT07479043.

Clinical trials, technology development, strategic collaborations, and regulatory activities are strengthening the ARDS treatment pipeline.

Regional Insights
North America 39.8% share: Leads the market due to advanced ICU infrastructure, high healthcare expenditure, strong clinical research, and adoption of advanced respiratory support technologies.

Europe 29.4% share: Growth is supported by advanced critical-care facilities, established clinical guidelines, and increasing adoption of sophisticated respiratory therapies.

Asia Pacific 22.6% share: Fastest-growing region, driven by expanding ICU capacity, rising respiratory disease burden, improving healthcare infrastructure, and increasing investments in critical-care technologies.

Latin America 4.5% share: Supported by improving hospital infrastructure, expanding access to intensive care, and growing demand for advanced respiratory support.

Middle East & Africa 3.7% share: Driven by healthcare modernization, increasing ICU investments, and expanding access to advanced respiratory treatment technologies.

Speak to our analyst and get customization in the report as per your requirements: https://www.datamintelligence.com/customize/acute-respiratory-distress-syndrome-treatment-market?sai-v

Key Segments
➥ By Treatment

Drug Class: Represents the dominant segment, driven by the widespread use of pharmacological therapies to manage underlying causes and complications of acute respiratory distress syndrome, including inflammation, infection, fluid imbalance, and associated critical conditions.

Device: Represents a significant segment, supported by increasing adoption of mechanical ventilation, high-flow oxygen therapy, extracorporeal membrane oxygenation (ECMO), and other respiratory support technologies for patients with severe ARDS.

➥ By Route of Administration

Oral: Represents a significant segment, supported by the use of oral medications for supportive management and treatment of underlying conditions associated with ARDS when patients are clinically able to receive enteral therapy.

Parenteral: Represents the dominant segment, driven by the critical condition of ARDS patients and the frequent need for intravenous administration of medications, antibiotics, fluids, sedatives, and other intensive-care therapies.

➥ By Sales Channel

Distribution Channel: Represents a significant segment, supported by the procurement of ARDS treatment drugs, respiratory devices, and critical-care products through pharmaceutical distributors, medical device distributors, and specialized healthcare supply networks.

End User: Represents the dominant segment, driven by direct utilization of ARDS treatment products across hospitals, intensive care units, specialty clinics, and other critical-care facilities managing severe respiratory conditions.

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.